Text Size




Home | Clinical Trials

FDA Approved Drugs » 1999
Medical Areas: Neurology | Obstetrics/Gynecology (Women’s Health)

View By:Year | Company | Conditions | Therapeutic Areas | Drug Names


The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company: Duramed Pharmaceuticals
Approval Status: Approved July 1999
Treatment Area: Obstetrics/Gynecology

General Information

Cenestin has been approved for the treatment of hot flashes, night sweats, and other moderate-to-severe vasomotor symptoms associated with menopause. Cenestin is a slow-release conjugated estrogen product that is synthesized 100% from soy and yam plants. Premarin, the only other slow-release conjugated estrogen product, is derived from pregnant horses.

Side Effects

In clinical trials, the most frequently reported adverse events were headache and insomnia, which occurred with similar frequency in the placebo group. Pregnant women should not use hormone replacement therapy because of possible risk to the fetus.

 Back to Top | Printer Friendly Version

Get Involved

Stroke and You

Our Mission Statement

National Stroke Association’s mission is to reduce the incidence and impact of stroke by developing compelling education and programs focused on prevention, treatment, rehabilitation and support for all impacted by stroke.

National Stroke Association

9707 E. Easter Lane, Suite B
Centennial, CO 80112